Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

RATIONALE: There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not to treat patients with preserved lung volume. OBJECTIVE: To investigate whether patients with IPF and preserved lung volume receive the same benefit from nint...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Thorax
Auteurs principaux: Kolb, Martin, Richeldi, Luca, Behr, Jürgen, Maher, Toby M, Tang, Wenbo, Stowasser, Susanne, Hallmann, Christoph, du Bois, Roland M
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2017
Sujets:
Interstitial Lung Disease
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520269/
https://ncbi.nlm.nih.gov/pubmed/27672117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2016-208710
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires